BGMS earnings analysis
What we found in BGMS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BGMS generated $336,000 of Q2 2026 revenue, down approximately 56.8% sequentially, while gross margin improved to approximately 23% from 18.4%. Diluted EPS declined to negative $0.08 from negative $0.04, although the net loss improved to $405,000 from $1.318 million in the comparable prior period. Liquidity remains dependent on cash resources estimated at $3.8 million through the first quarter of 2027, and the company completed a $794,403 equity financing involving 1,103,338 shares. No formal numeric revenue or EPS guidance was provided and management reported no material changes to the 2025 Form 10-K risk factors.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q2 Revenue Declined Sequentially
- Q2 2026 revenue was $336,000, down approximately 56.8% from $778,000 in Q1 2026. The filing information provided does not include a comparable prior-year Q2 revenue figure.
- Gross Margin Improved
- Gross margin improved to approximately 23% from 18.4% in Q1 2026, an increase of about 4.6 percentage points.
- EPS Weakened Sequentially
- Diluted EPS was negative $0.08 versus negative $0.04 in Q1 2026, indicating sequential earnings deterioration despite the improved gross margin.
- Net Loss Narrowed
- Net loss improved to $405,000 from $1.318 million in the comparable prior period, while general and administrative expense also improved, according to the reported quarterly results.
- Equity Funding Completed
- The company raised gross proceeds of $794,403 through the sale of 1,103,338 common shares at $0.72 per share on June 10, 2026.
- Liquidity Outlook Extends Into 2027
- Management estimated that $3.8 million of cash resources would fund planned expenditures into the first quarter of 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No Formal Risk-Factor Changes
- The company states that there have been no material changes to the risk factors in its December 31, 2025 Form 10-K. This filing therefore provides no evidence of a formal risk-factor reduction or expansion.
- Director Litigation Exposure
- A shareholder-related lawsuit against the CEO and directors seeks approximately $12 million in damages. The company is not a party, all defendants have moved to dismiss, and no amounts were accrued because a loss was not considered probable.
- Equity Dilution and Resale Pressure
- The June 10, 2026 financing issued 1,103,338 shares for gross proceeds of $794,403, creating additional dilution for existing shareholders. The concurrent registration-rights agreement requires the resale registration statement to remain continuously effective until the registrable securities are sold or cease to qualify.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.08
- Gross margin
- 23.0%
- Segment
- Fire Safety: $336,000 of revenue in Q2 2026
What they said about what is next.
No formal numeric revenue or EPS guidance was provided. Management estimated that $3.8 million of cash resources would fund planned expenditures into the first quarter of 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Bio Green Med Solution, Inc. reported revenues of $666,000 for Q4 2025, a significant increase from $81,000 in the prior quarter, and a more substantial movement from $0 reported last year. However, the company reported…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BGMS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever